Human Papillomavirus type 16 (HPV-16) is the cause of both benign lesions and ano-genital cancers. In HPVassociated cancers the transforming properties of the expressed viral E6 and E7 proteins have been revealed by a number of dierent assays. We have generated transgenic mice expressing HPV-16 E6/E7 genes under the control of the murine keratin 5 gene promoter, which should confer cell-type speci®c expression in the basal cells of squamous strati®ed epithelia. Transgenic mice developed thymic hyperplasia and lung neoplasia with 100% frequency, the thymus showing a size increase at 2 months and reaching the maximum dimension at 6 months, when lung carcinomas appeared. After this time the size of hyperplastic thymi decreased, while malignant formations invaded the mediastinal area. Hepatic metastasis could be also observed in some of the animals at the autopsy and death invariably occurred around 10 ± 11 months of age. Oncogene (2001) 20, 8148 ± 8153.
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Keywords: human Papillomavirus type 16; E6/E7 oncogenes; transgenic mice; lung carcinomas; thymic hyperplasia Human papillomaviruses (HPVs) are DNA tumor viruses that induce a wide range of hyperplastic and neoplastic lesions in cutaneous and mucosal epithelia (reviewed by zur Hausen and de Villiers, 1994; zur Hausen, 1996) . Several lines of evidence indicate that the E6 and E7 gene products of`high risk' HPVs play an important role in the initiation of tumor formation, mainly by interacting with cellular tumor suppressors (reviewed by zur Hausen, 2000; Butel, 2000) .
E6 and E7 genes cooperate with each other (Munger et al., 1989a; Sedman et al., 1992) and with other oncogenes (Bedell et al., 1989; Phelps et al., 1988; Storey et al., 1988; Storey and Banks, 1993) in the immortalization or transformation of cells. The transforming activities of E6 and E7 are dependent on the interaction with cellular tumor suppressor proteins, p53 and pRB, which regulate cell division, dierentiation and/or apoptosis (Heck et al., 1992; Mansur and Androphy, 1993; Nakagawa et al., 1995) . E6 binds to p53, which normally acts to increase the level of p21 (el-Deiry et al., 1993) , a cyclin kinase inhibitor (Harper et al., 1993; Hunter and Pines, 1994; Grana and Reddy, 1995; Sherr and Roberts, 1999) . As a result of this interaction p53 is rapidly inactivated through an ubiquitin-proteasomal degradation pathway (Schener et al., 1990 (Schener et al., , 1993 Lechner and Laimins, 1994) . Other cellular targets have been identi®ed for E6, i.e. ERC55, a putative calcium binding protein (Chen et al., 1995) ; paxillin, a protein involved in signal transduction (Tong and Howley, 1997) ; hDlg, the human homolog of the Drosophila discs large tumor suppressor protein (Kiyono et al., 1997; Lee et al., 1997; Pim et al., 2000) ; the interferon regulatory factor 3 (Ronco et al., 1998) ; and E6TP1, a putative GTPase-activating protein (Gao et al., 1999) .
On the other hand, E7 stabilizes p53 (Jones et al., 1997; Seavey et al., 1999) , but is able to inactivate the retinoblastoma susceptibility protein (pRB) thus promoting the entry of resting cells into S phase (Dyson et al., 1989; Munger et al., 1989b; Chellappan et al., 1992; Boyer et al., 1996; Ruesch and Laimins, 1997; Morozov et al., 1997) . The interaction of E7 with the RB-related pocket proteins makes them unable to associate to members of the E2F transcription factor family (McIntyre et al., 1996; Jones et al., 1997; Dyson, 1998) , thus inducing cell-cycle progression and S phase entry. In addition, HPV-16 E7 is able to uncouple cellular proliferation and dierentiation by targeting p21
Cip1 (Jones et al., 1997; Funk et al., 1997) and p27
Kip1 (Zerfass-Thome et al., 1996) . The contribution of E6 and E7 to the development of tumors in vivo has been widely studied by the use of transgenic mouse models (reviewed by Eckert et al., 2000) .
A variety of HPV 16 and HPV 18 transgenic mice have been generated which develop pre-malignant and malignant lesions correlating with the expression of the E7 gene by itself or in combination with E6. Although promoters with a wide range of tissue speci®city (Kondoh et al., 1991; Arbeit et al., 1993) were also used, in most cases the expression of the HPV oncogenes has been speci®cally targeted to epithelial cell type Griep et al., 1993; Arbeit et al., 1994; Pan and Griep, 1994; Howes et al., 1994; Auewarakul et al., 1994; Ledent et al., 1995; Comerford et al., 1995; Herber et al., 1996) . Expression of HPV 16 E6 and E7 driven by the human keratin 14 (K14) gene promoter in transgenic mice induced squamous carcinoma exclusively in the vagina and cervix of transgenic females following prolonged exposure to sex hormones (Coussens et al., 1996) .
The individual contribution of E6 and E7 has been investigated in transgenic mice models (Howes et al., 1994; Pan and Griep, 1994) . Herber et al. (1996) reported that HPV16 E7 oncogene under the control of K14 gene promoter induced squamous epithelial hyperplasia with high penetrance and only a fraction of the transgenic mice develop skin tumors late in life (Herber et al., 1996) . In contrast, HPV16 E6 oncogene appears to be sucient to induce carcinomas (Song et al., 1999) .
In this study we describe a line of mice transgenic for the HPV16 E6/E7 oncogenes under the control of the murine keratin 5 (K5) gene promoter ( Figure 1a) . Keratin 5 is a high molecular weight (58 Kd) cytokeratin which is distributed in basal cells of strati®ed and pseudostrati®ed epithelia (Nelson and Sun, 1983; Moll et al., 1989; Byrne and Fuchs, 1993) .
Because of the cell-speci®city of the K5 gene promoter (Missero et al., 1993; Byrne and Fuchs, 1993; Ramirez et al., 1994; Murillas et al., 1995) , the expectation was to ®nd expression of the E6/E7 oncogenes mainly in the skin squamous epithelium. Surprisingly, while transcription ( Figure 1b ) and protein expression was found in the tail skin, only a mild epidermis hyperplasia was observed (data not shown).
The mice described in this study, developed a severe thymic hyperplasia by 3 months of age with an increase of transgenic thymus weight up to four-fold over the weight of the organ of non-transgenic littermate. The thymus reached the maximum weight at 6 months of age (Figure 2a,b) , the time of lung neoplasm appearance. Then after, the thymus size started to decrease (Figure 2b ), still expressing E6/E7 oncogenes ( Figure  1b ) and the neoplastic formation became invasive. Multiple lung carcinomas with high penetrance (Figure  3a ,b) and liver metastasis (Figure 3h ) could be found by 9 months. This is compatible with the expression of K5 in thymus reticulum cells (Moll et al., 1989; Klug et al., 1998) and basal cells of pseudostrati®ed respiratory epithelium (Moll et al., 1989) . Thymic hyperplastic/ neoplastic lesions have been observed in transgenic mice carrying other oncogenes driven by the K5 promoter: alterations of thymic cortical-medullary boundary in mice transgenic for the neu oncogene (Bol et al., 1998) ; a severe thymic hyperplasia in transgenic mice expressing the human cyclin D1 gene (Robles et al., 1996) or the cyclin D2 gene (Rodriguez- (Seedorf et al., 1985) were inserted into a derivative of K5T plasmid (Missero et al., 1993) named K5Ti which contains 900 bp of the mouse keratin 5 promoter, an adenovirus type 2/ mouse IgG variable region hybrid intron (Huang and Gorman, 1990 ) and the SV40 polyadenylation site. The puri®ed fragment derived from BamH1 digestion of the plasmid was used to generate transgenic mice by pronuclear microinjection (Hogan et al., 1986) . (b) Two out of 12 newborn mice were found to be positive for the integration of the transgene by PCR analysis. The transgene copy number was estimated by Southern blot analysis. One founder (2303) had at least two copies arranged in a head-totail tandem array while the other (2301) had approximately 20 copies of DNA (data not shown). The litters born from the mouse 2301 harboring 20 copies of the transgene were not surviving longer than few days and this founder died at 10 months of age. An autopsy was not performed because the death was not discovered for 48 h. The expression of the transgene was analysed by RT ± PCR of the RNA extracted (Chomczynski and Sacchi, 1987) . Two bands were observed: a 724 bp band consistent with the full-length E6/E7 transcript and a band of 538 bp due to the formation of E6*I/E7 spliced transcript (Smotkin et al., 1989) (b) . E6*II/E7 spliced transcript was not visible. However Smotkin et al. (1989) have suggested that E6*I may provide for more ecient translation of E7 than E6*II. Lanes: 1: Transgenic Thymus (age 9 months); 2: Transgenic thymus (age 10 months); 3: Tail skin founder 2303; 4: Tail skin of non transgenic control; 5: Tail skin founder 2301
Oncogene HPV-16 E6/E7-mediated tumorigenesis in transgenic mice L Carraresi et al Figure 2 Transgenic thymi analysis. (a) Macroscopic representation of a thymus derived from a 6 months old transgenic mouse weighting 2,178 grams. (b) Time frame of thymic hyperplasia development. Thymi from control and transgenic mice were harvested and weighted at the age indicated in the abscissa. At the bottom of this panel are also indicated the time of appearance and the number of animals with lung tumors. (c) Cyto¯uorimetric analysis of thymocyte subset distribution in control and transgenic mice at the age of 6 months. The thymi were removed, weighted and then washed twice with PBS. Tissues were digested with a collagenase solution (200 units/ml in DMEM medium) for 2 h. Thymocytes were isolated through a Percoll gradient centrifugation. Thymic cells were stained using anti-CD8 (Ly-2) FITC conjugated and anti-CD4 (L3T4) PE conjugated monoclonal antibodies (PHARMINGEN San Diego, CA, USA). Collection of 10,000 stained cells was performed by using a FACS-Calibur (Becton Dickinson, San Jose, CA, USA) and the analysis was carried out by using a Cell-Quest software (Becton Dickinson). (d ± g) Histology and immunohistochemistry analysis. Thymi were removed, ®xed with 10% buered formaldehyde, paran embedded and sectioned. For histopathological examination, sections were stained with hematoxylin and eosin. Immunohistochemistry was carried out using antibodies against E7 (HPV 16-E7 (N-21), Santa Cruz Biotechnology, Santa Cruz, California, USA) by the peroxidaseantiperoxidase (Dako, Denmark) method and counterstained with hematoxylin. (d) Hematoxylin/eosin stained section of a non transgenic thymus at 1 month of age; (e) Hematoxylin/eosin stained section of a thymus derived from a 6 months old transgenic mouse. (f) Immunohistochemistry of a control thymus and (g) of a thymus from a 6 months old transgenic mice. Original magni®cation: 2506(d, e, g); 1506(f) et al., 2000) as well as in p27 Kip1 -de®cient mice (Fero et al., 1996; Nakayama et al., 1996) . The hyperplastic thymi of the mice described in this report, displayed a normal organization (Figure 2e ), i.e, an outer compartment (cortex) and an inner compartment (medulla). Deregulation of the epithelial cell proliferation has no in¯uence in the dierentiation program, probably because the overgrowing epithelial cells provide an ever growing environment for the development of T-cells. No major alterations were evident in the thymocyte subset distribution as de®ned by cyto¯uorimetric analysis of CD4 and CD8 expressing cells (Figure 2c ). The hyperplastic thymus phenotype was observed in transgenic mice expressing the human cyclin D1 under the direction of the bovine K5 gene promoter (Robles et al., 1996) . In the latter transgenic model, cyclin D1 overexpression contributes to deregulation of cyclinD/RB growth regulatory pathway. Similarly, in our model, E7 inactivation of pRB, abrogation of CKI activity and subsequent release of E2F transcription factors may induce S phase entry.
Lung cancer is a leading cause of tumor-related deaths in humans, but its origin and development are poorly understood. To date, few models have been available to study the biology of these tumors (Damak et al., 1996; Ogawa et al., 1996; Morris et al., 1998) . Our transgenic mice developed brochiogenic lung cancer as early as 6 months after birth and the E6/ E7 genes were eciently expressed in pre-neoplastic ( Figure 3g ) and neoplastic cells (Figure 3c,d) . The transgenic mice lung tumors showed a progression from in situ (Figure 3f ) to invasive carcinoma ( Figure  3b) . In a minor percentage liver metastases were observed (Figure 3h ). The latency of tumor development, suggests the requirement of a secondary event for these E6/E7-expressing cells to become neoplastic, as observed for other mice models of lung carcinogenesis induced by myc (Leder et al., 1986) , ras (Sunday et al., 1999) and SV40 T-antigen (Sandmoller et al., 1995) . The presence of HPV DNA is frequently found in human bronchopulmonary carcinomas (Hirayasu et al., 1996; Hennig et al., 1999; Clavel et al., 2000) . In addition, inactivation of p53 and pRB occurs in the majority of neuroendocrine lung carcinomas in humans (Gouyer et al., 1998; Sampietro et al., 2000) and in mice (Nikitin et al., 1999) . These observations strongly suggest that E6/E7 expression most probably causes lung cancer in our transgenic model, through the inactivation of p53 and pRB. On the other hand, we cannot rule out that lung tumors in the transgenic line we have analysed so far, are the result of the transgene integration site, since up to now only one founder of the two produced survived the time for reproduction and establishment of the transgenic line. It is evident that further studies are required to completely characterize this line of transgenic mice. Because of the complexity of p53 and pRB modulation of the cell cycle, it should be of great interest the use of this transgenic model to study and compare, in vivo, the molecular mechanisms underlying two pathological events: thymic hyperplasia and lung carcinomas.
